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Abstract.
BACKGROUND: Colorectal cancer (CRC) is a major cause of cancer-related deaths world-wide. Detection of molecular mark-
ers in stool samples is a promising strategy for CRC screening. MicroRNAs (miRNAs) are short, non-coding RNA molecules
that are commonly dysregulated in neoplasia.
OBJECTIVE: The objective of this study was to evaluate the fecal miRNAs differentiation between early-stage CRC patients
and healthy subjects.
METHODS: Stool samples were collected from 40 patients with early stage (I, II) CRC and 16 healthy controls. RNA was
extracted from all samples using miRNAeasy Mini Kits. MiRNA microarray expression profiling was performed with Agilent’s
miRNA Microarray system on 12 CRC and 8 normal stool samples. The expression levels of miR-4478 and miR-1295b-3p were
determined by the SYBR Green miScript PCR system.
RESULTS: In profiling study, we found 215 down-regulated miRNAs in CRC group. Furthermore, in validation study we found
that the expression levels of fecal miR-4487 and miR-1295b-3p were significantly decreased in CRC patients compared to healthy
controls.
CONCLUSIONS: The expression of miR-4478 and miR-1295b-3p were significantly diminished in stool samples of CRC
patients with early stage (I, II) in comparison with normal group. These miRNAs may be used as potential non-invasive molecular
markers for CRC diagnosis, but further studies are needed.
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1. Introduction
Colorectal cancer (CRC) is the third most common
cancer in men and the second in women worldwide [1]
with an estimated 1.4 million new cases and with more
than half million deaths annually [2,3]. The survival
rate of CRC patients is significantly dependent on the
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stage of disease at the time of diagnosis. Grave conse-
quences will follow for patients who have been diag-
nosed in the terminal phases of the disease [4]. Since
great proportion of CRC cases develop from precancer-
ous lesions, accurate screening could greatly improve
the chance of treatment and survival rate [5]. Although
colonoscopy is currently the most reliable method for
CRC screening, it is not generally accepted due to its
invasive nature and high cost [6]. FOBT (Fecal Oc-
cult Blood Test) is a non-invasive procedure for CRC
screening, but its sensitivity and specificity is low [5].
Therefore, to develop new non-invasive and early di-
agnostic methods are highly needed..
MicroRNAs (miRNAs) are short (18–25 nt) non-
coding RNAs that regulate gene translation and can be
used as markers for various disease [7]. Nowadays, uti-
lization of miRNA provides a promising opportunity
for early detection of cancers. Changes in miRNAs ex-
pression have been observed in several types of can-
cer, including CRC [8–11]. MiRNAs have been shown
to be stably present in a wide range of clinical speci-
mens [12–14] such as stool samples [15,16].
Stool specimens are in direct contact with the
colonic luminal surface and may contain colonocytes
and tumoral cells in carcinoma cases [17,18]. These
cells carry important genetic and epigenetic informa-
tion that can be used as diagnostic biomarkers in
CRC [19–21]. In the present study, we have investi-
gated the feasibility of using fecal miRNAs in early di-
agnosis of CRC patients.
2. Materials and methods
2.1. Patients
A total of 40 stool samples from primary CRC pa-
tients (Stage I, II) were collected from August 2011
to March 2013 at Digestive Disease Research Institute
(DDRI), Shariati Hospital, Tehran University of Med-
ical Science. The histology was confirmed and staged
according to the tumor-node-metastasis (TNM) stag-
ing system of the International Union Against Cancer.
In the control group, 16 stool samples were collected
from individuals proven to be free of colonic disease
with colonoscopy. The control group was matched to
the CRC patient group in terms of age and gender.
No significant differences were observed between the
CRC patients and controls in age (p = 0.101) or gender
distribution (p = 0.414). Clinical and demographical
data of the patients and the controls are presented in Ta-
Table 1
Patients’ demographics: characteristics of CRC patient and control
Characteristic CRC patient Control p value
Age 63 ± 9.03 59.5 ± 8.64 0.101a
Gender Male: 23 8 0.414a
Female: 17 8
TNM stage I 11 −
II 29 −
Tumor location Colon 35 −
Rectum 5 −
ap value for age was calculated by independent sample t-test; p val-
ues for gender was calculated by Fisher’s exact test.
ble 1. The samples were quickly frozen at −70◦C un-
til subsequent analysis. Written informed consent was
obtained from each participant.
2.2. RNA isolation
Total RNA (including small RNA) was extracted
from stool samples using miRNAeasy Mini Kits (Qia-
gen) according to the manufacturer’s instructions with
some modifications. Briefly, approximately 100 mg
of stool was homogenized with 1000 µL RNase free
water and 200 µL of this homogenate was lysed in
a proportion of 1:6 with QIAzol lysis reagent (Qia-
gen, Valencia, CA). After homogenization, RNA was
precipitated with chloroform. The aqueous phase was
mixed with 1.5 volumes of 100% ethanol. The con-
centration of extracted RNA was measured using the
NanoDrop-1000 Spectrophotometer (Thermo Fisher
Scientific Inc., Wilmington, DE), and Agilent’s Bioan-
alyzer (Agilent Technologies, Palo Alto, CA) was used
for checking the quality of total RNA with the RNA
6000 chip and miRNA with the small RNA chip.
2.3. MiRNA microarray expression profiling and data
analysis
Stool samples from 12 CRC patients (including 3
cases of stage I and 9 cases of stage II) and 8 healthy
controls were used for miRNA profiling study. The
miRNA expression profiles were generated by Agi-
lent’s miRNA Microarray system (Release 19.0), con-
taining 2006 human miRNAs (Agilent Technologies,
Santa Clara, CA). Labeling and hybridization of RNA
samples were performed according to the Agilent’s
protocol. Microarray data processing was performed
with Agilent’s Feature Extraction Software with de-
fault parameters. The statistical analyses of microar-
ray data were performed with the GeneSpring GX ver-
sion 12.0 Analysis Software (Agilent). Data were pre-
processed by log 2 transformation and normalization
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between all arrays was done by the 75th percentile
method. Differences between the two groups were an-
alyzed using t-test for those miRNAs with at least
a 2-fold change in expression level between the two
groups. Only those miRNAs with P value < 0.05, q
value< 0.3 were considered as significantly changed.
2.4. MiRNA quantification by quantitative reverse
transcriptase polymerase chain reaction
(qRT-PCR)
A total of 40 stool samples from CRC patients (stage
I, n = 11; stage II, n = 29) and 16 stool samples
from healthy controls were used for qRT-PCR in the
validation study. The miRNA microarray results were
validated using a SYBR Green method. Reverse tran-
scription of RNA was performed with the miScript Re-
verse TranscriptionKit (Qiagen, Valencia, CA) accord-
ing to the manufacturer’s guidelines. Real-time PCR
was performed on a Roche Light-cycler, software v.3.5
(Roche Applied Science, Mannheim, Germany) by the
SYBR Green miScript PCR system (Qiagen, Valen-
cia, CA) according to the manufacturer’s instructions.
Each reaction was performed in a 20 µL volume with
10 ng template cDNA. All reactions were run in du-
plicate. The most significant differentially expressed
miRNAs, miR-4478 and miR-1295b-3p, were selected
for validation study. The RNU6B (Qiagen) was used
as an endogenous control for normalization of data.
The relative quantification (RQ) for each miRNA com-
pared with RNU6B and evaluation of statistically sig-
nificant differences in miRNA expression between the
two groups were calculated using ΔΔCq method and
GraphPad Prism (V.6) software respectively. P values




We isolated an adequate amount of total RNA, in-
cluding miRNA in stool samples of all CRC patients
and normal subjects, following optimization of the
commercial RNA extraction protocols.
Microarray analysis was performed to reveal the
miRNAs differentially expressed in stool samples of
12 CRC patients and 8 normal subjects. We found
215 significantly altered miRNAs which were down-
regulated in CRC group compared to the control group.
The complete list of differentially expressed miRNAs
between primary CRC patients and healthy subjects is
provided in Supplementary Table S1.
Fig. 1. MiR-4487 down-regulation in the fecal samples from CRC
patients compared to the normal group (P value 0.017). Expression
levels of the miR-4487 are normalized to RNU6B (Non-parametric
Mann-Whitney t-test).
Fig. 2. Fecal miR-1295b-3p expression levels were down-regulated
in CRC patients compared to normal subjects (P value 0.013). Ex-
pression levels of miR-1295b-3p were normalized to RNU6B (Non–
parametric Mann-Whitney t-test).
3.2. Validation of miRNA expressions by qRT-PCR
To confirm the accuracy of the data obtained from
microarray, two miRNAs, miR-4478 and miR-1295b-
3p, the most significant miRNAs, were selected for fur-
ther validation by qRT-PCR. A significant alteration
was noticed in the levels of these miRNAs: miR-4478
(P = 0.017) (Fig. 1) and miR-1295b-3p (P = 0.013)
(Fig. 2) were significantly down-regulated in the CRC
group.
Receiver operating characteristic (ROC) curve anal-
ysis for the differential expression of miR-4487 and
miR-1295b-3p between CRC patients and normal in-
dividuals revealed that these miRNAs are potentially
valuable to be used as diagnostic biomarkers. The area
198 R. Ghanbari et al. / Decreased expression of fecal miR-4478 and miR-1295b-3p in early-stage colorectal cancer
Fig. 3. Area under curve (AUC) of receiver operating characteristic (ROC) for miR-4487 and miR-1295b-3p. (Colours are visible in the online
version of the article; http://dx.doi.org/10.3233/CBM-140453)
under the curve (AUC value) for miR-4487 was 70%
with the standard error of 0.075 (P value = 0.017)
while the AUC value for miR-1295b-3p was 71% with
the standard error of 0.072 (P value = 0.014) (Fig. 3).
4. Discussion
MiRNAs have been shown to exist stably more than
other nucleic acids and proteins in a broad range of
clinical specimens [12,13] including stool samples [15,
16]. Moreover, their expression levels are generally
representative of the tumorous tissues. Therefore, de-
termining the expression level of miRNAs in stool may
serve as a suitable non-invasive diagnostic, prognos-
tic and biomarkers in CRC [22]. Over the past few
years, a large number of differentially expressed miR-
NAs have been identified in colorectal cancer. The first
study on detection of fecal miRNA in CRC patients
was reported by Ahmed et al in 2009, who identified
7 over-expressed and 7 under-expressed miRNAs [16].
MiR-320 was one of the miRNAs with decreased ex-
pression, which consistently confirmed in our profil-
ing study. In separate subsequent studies, up-regulation
of miR-92a [23], miR-21 [23,24], miR-17-92 cluster
and miR-135 [25], as well as miR-106a [24] and miR-
144 [15] have been reported in stools of the CRC pa-
tients but not in the controls. Li et al. reported re-
cently down-regulation of fecal miR-143 and miR-145
in CRC patients [26].
In the present study, we investigated the fecal miR-
NAs in patients with early stage (I, II) CRC. We found
215 differentially expressed miRNAs in the patient
group. Moreover, in a validation study by qRT-PCR,
we demonstrated that the stool levels of miR-4478 and
miR-1295b-3p have been significantly decreased in the
CRC patients compared to the healthy subjects.
MiR MiR-4478 has the ability to bind to 3’-UTR of
the class II Histone deacetylase (HDAC4) [27], which
is a regulator of colon cells proliferation [28]. HDAC4
frequently overexpressed in several malignancies in-
cluding CRC [29] and promotes growth of colon can-
cer cells via repression of p21 [28,30]. Moreover, de-
creased expression of miR-1295 has been already re-
ported in CRC tissue samples [31].
All of our patients were in early and curable stages
(I, II) of CRC. Worth of mentioning is that in these
early-stage tumors miR-4478 and miR-1295b-3p were
down-regulated and thus may serve as a novel non-
invasive biomarker for diagnosis of this neoplasia.
Nevertheless, this finding requires further validation
studies on larger set of samples of different histopathol-
ogy and stages (hyperplasia, adenoma, carcinoma and
metastasing carcinoma). The current study serves as a
basis for subsequent investigations on identification of
target genes of these detected miRNAs and determine
the expression rate of these target genes and their cor-
responding proteins to identify their potential effects
on the CRC tumorigenicity.
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Supplemental material
Supplement Table 1
Differentially expressed miRNAs in fecal samples of CRC patients
miRNA P FC1 miRNA P FC miRNA P FC miRNA P FC
4478 0.0009 10.66 1226-5p 0.009 10.05 3147 0.02 8.48 1227-5p 0.03 5.75
1295b-3p 0.001 16.00 5739 0.01 8.05 3177-3p 0.02 8.72 5703 0.03 5.89
124-3p 0.002 10.76 4515 0.01 9.76 193b-5p 0.02 8.12 4497 0.03 6.00
320a 0.002 10.59 3648 0.01 7.61 4507 0.02 8.06 4442 0.03 4.55
3185 0.002 16.00 631 0.01 7.09 3141 0.02 7.57 4800-5p 0.03 5.28
3605-5p 0.002 10.90 629-3p 0.01 10.48 3610 0.02 6.48 4651 0.03 5.25
4688 0.002 11.61 760 0.01 7.76 3620-5p 0.02 8.26 4632-5p 0.03 6.27
3911 0.002 16.00 4634 0.01 7.86 6076 0.02 8.85 3917 0.03 16.00
1247-3p 0.003 9.10 4665-5p 0.01 7.05 3186-3p 0.02 16.00 4538 0.03 6.65
4451 0.003 12.38 4465 0.01 7.00 let-7b-5p 0.02 12.28 1587 0.04 6.22
4640-3p 0.003 16.00 6126 0.01 6.22 1202 0.02 6.06 149-3p 0.04 5.25
1260a 0.003 16.00 4286 0.01 11.81 4738-3p 0.02 6.70 4476 0.04 5.59
494 0.003 13.03 518c-5p 0.01 6.88 150-3p 0.02 6.06 4505 0.04 5.43
6085 0.003 16.00 4793-5p 0.01 6.14 584-5p 0.02 11.15 4459 0.04 5.28
4690-5p 0.003 10.70 6133 0.01 8.63 602 0.02 7.36 320b 0.04 5.95
4454 0.003 16.00 526b-5p 0.01 6.70 3196 0.02 6.75 4257 0.04 6.69
4428 0.004 8.19 622 0.01 8.59 483-5p 0.02 5.40 4788 0.04 4.82
33a-3p 0.004 16.00 550a-5p 0.01 7.84 4327 0.02 6.57 4741 0.04 5.03
1233-1-5p 0.004 8.16 4698 0.01 6.56 5006-5p 0.02 5.18 33b-3p 0.04 7.08
1236-5p 0.004 7.46 4486 0.01 6.36 766-3p 0.02 7.12 5195-3p 0.04 6.47
3200-5p 0.005 10.52 623 0.01 6.86 133b 0.02 14.20 1281 0.04 9.72
4513 0.005 9.26 5088 0.01 5.64 3614-5p 0.02 11.56 933 0.04 8.94
5190 0.005 12.89 4271 0.01 9.96 1229-5p 0.02 4.67 638 0.04 5.21
4259 0.005 9.28 4672 0.01 7.56 3188 0.02 5.35 197-5p 0.04 4.21
4648 0.005 7.08 1273g-3p 0.01 7.90 4710 0.02 5.96 191-3p 0.04 7.07
574-5p 0.005 12.49 302c-5p 0.01 7.48 4743-5p 0.02 6.42 4323 0.04 8.58
3195 0.005 12.24 193a-5p 0.01 12.61 575 0.02 5.72 658 0.04 4.33
483-3p 0.005 16.00 3652 0.01 8.60 3937 0.02 5.94 6724-5p 0.04 4.91
4746-3p 0.005 16.00 3176 0.01 16.00 4484 0.02 5.03 4322 0.04 5.60
4532 0.006 9.02 3682-3p 0.01 8.19 5189 0.02 4.92 1207-5p 0.04 6.35
663a 0.006 14.24 3180-5p 0.01 16.00 4664-3p 0.02 6.20 939-5p 0.04 5.11
4776-5p 0.006 7.67 4669 0.02 7.58 6510-5p 0.02 5.01 671-5p 0.04 5.60
4419a 0.006 8.47 1469 0.02 12.71 4429 0.02 4.91 2276 0.04 5.50
4430 0.006 6.42 1914-3p 0.02 6.87 6127 0.03 5.49 4749-3p 0.04 6.35
3174 0.006 14.33 765 0.02 7.09 211-3p 0.03 6.34 1246 0.04 6.09
3676-5p 0.007 10.18 3173-3p 0.02 14.94 4745-5p 0.03 5.25 6068 0.04 5.29
1287 0.007 12.82 4298 0.02 8.41 345-3p 0.03 4.29 324-3p 0.04 4.71
3934-5p 0.007 16.00 371a-5p 0.02 7.17 4534 0.03 6.02 4767 0.04 7.37
6717-5p 0.007 12.58 652-5p 0.02 6.75 188-5p 0.03 6.28 1234-3p 0.04 6.05
6511b-5p 0.007 7.78 3194-5p 0.02 6.73 6507-5p 0.03 10.48 1225-3p 0.045 6.13
3646 0.007 11.93 1182 0.02 7.30 711 0.03 4.79 498 0.045 5.22
601 0.007 10.34 5001-5p 0.02 6.21 3124-5p 0.03 7.84 1304-3p 0.045 9.42
4485 0.007 10.29 3667-5p 0.02 5.90 5787 0.03 6.91 6165 0.046 4.44
3935 0.008 12.04 4655-5p 0.02 7.19 762 0.03 5.74 3659 0.047 6.28
4496 0.008 7.71 877-5p 0.02 6.55 572 0.03 6.93 937-5p 0.047 5.96
125a-3p 0.008 13.30 4728-5p 0.02 5.46 4499 0.03 7.89 6125 0.047 5.00
874 0.009 7.90 5196-5p 0.02 7.77 3137 0.03 4.69 525-5p 0.048 6.42
4419b 0.009 8.29 6086 0.02 6.04 4758-5p 0.03 7.25 1237-3p 0.048 5.98
514b-5p 0.009 7.14 4721 0.02 6.19 3162-5p 0.03 7.42 4656 0.049 4.28
718 0.009 9.75 642a-3p 0.02 5.73 4443 0.03 6.03 3680-3p 0.049 16.00
4261 0.009 10.43 5100 0.02 14.13 6723-5p 0.03 5.00 4466 0.049 5.42
320d 0.009 8.86 636 0.02 5.64 3138 0.03 4.45 1238-3p 0.049 6.01
4444 0.009 7.55 769-3p 0.02 9.49 4313 0.03 7.32 4665-3p 0.049 6.17
583 0.009 9.76 1185-1-3p 0.02 6.68 3663-3p 0.03 4.85
1FC: Fold change.
